Skip Navigation

European Heart Journal 2000 21(24):2071-2078; doi:10.1053/euhj.2000.2476
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (207)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Connolly, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Connolly, S. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials

S. J. Connollyf1, A. P. Hallstrom, R. Cappato, E. B. Schron, K.-H. Kuck, D. P. Zipes, H. L. Greene, S. Boczor, M. Domanski, D. Follmann, M. Gent and R. S. Roberts investigators of the AVID, CASH and CIDS studies

revised October 22, 2000; accepted October 4, 2000

Abstract

Aims Three randomized trials of implantable cardioverter defibrillator (ICD) therapy vs medical treatment for the prevention of death in survivors of ventricular fibrillation or sustained ventricular tachycardia have been reported with what might appear to be different results. The present analysis was performed to obtain the most precise estimate of the efficacy of the ICD, compared to amiodarone, for prolonging survival in patients with malignant ventricular arrhythmia.

Methods and Results Individual patient data from the Antiarrhythmics vs Implantable Defibrillator (AVID) study, the Cardiac Arrest Study Hamburg (CASH) and the Canadian Implantable Defibrillator Study (CIDS) were merged into a master database according to a pre-specified protocol. Proportional hazard modelling of individual patient data was used to estimate hazard ratios and to investigate subgroup interactions. Fixed effect meta-analysis techniques were also used to evaluate treatment effects and to assess heterogeneity across studies. The classic fixed effects meta-analysis showed that the estimates of ICD benefit from the three studies were consistent with each other (P heterogeneity=0·306). It also showed a significant reduction in death from any cause with the ICD; with a summary hazard ratio (ICD:amiodarone) of 0·72 (95% confidence interval 0·60, 0·87;P=0·0006). For the outcome of arrhythmic death, the hazard ratio was 0·50 (95% confidence interval 0·37, 0·67;P<0·0001). Survival was extended by a mean of 4·4 months by the ICD over a follow-up period of 6 years. Patients with left ventricular ejection fraction ≤35% derived significantly more benefit from ICD therapy than those with better preserved left ventricular function. Patients treated before the availability of non-thoracotomy ICD implants derived significantly less benefit from ICD therapy than those treated in the non-thoracotomy era.

Conclusion Results from the three trials of the ICD vs amiodarone are consistent with each other. There is a 28% reduction in the relative risk of death with the ICD that is due almost entirely to a 50% reduction in arrhythmic death.

Key Words: Amiodarone, implantable cardioverter defibrillator, meta-analysis, cardiac arrest, ventricular tachycardia

f1 Correspondence: Stuart J. Connolly, MD, Hamilton Health Sciences Corporation, Hamilton General Site, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. Mark Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2085 - 2105.
[Full Text] [PDF]


Home page
CirculationHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation, May 27, 2008; 117(21): 2820 - 2840.
[Full Text] [PDF]


Home page
CirculationHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation, May 27, 2008; 117(21): e350 - e408.
[Full Text] [PDF]


Home page
JNMHome page
D. Nagahara, T. Nakata, A. Hashimoto, T. Wakabayashi, M. Kyuma, R. Noda, S. Shimoshige, K. Uno, K. Tsuchihashi, and K. Shimamoto
Predicting the Need for an Implantable Cardioverter Defibrillator Using Cardiac Metaiodobenzylguanidine Activity Together with Plasma Natriuretic Peptide Concentration or Left Ventricular Function
J. Nucl. Med., February 1, 2008; 49(2): 225 - 233.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
T. Rossenbacker, S. G. Priori, and D. P. Zipes
The fight against sudden cardiac death: consensus guidelines as a reference
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I50 - I58.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
P. Vassallo and R. G. Trohman
Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications
JAMA, September 19, 2007; 298(11): 1312 - 1322.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
S. Singh and M. M. Murawski
Implantable Cardioverter Defibrillator Therapy and the Need for Concomitant Antiarrhythmic Drugs
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 175 - 180.
[Abstract] [PDF]


Home page
CMAJHome page
D. H. Birnie MB ChB MD, C. Sambell BSc, H. Johansen PhD, K. Williams MS, R. Lemery MD, M. S. Green MD, M. H. Gollob MD, D. S. Lee MD PhD, and A. S.L. Tang MD
Use of implantable cardioverter defibrillators in Canadian and US survivors of out-of-hospital cardiac arrest
Can. Med. Assoc. J., July 3, 2007; 177(1): 41 - 46.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. S. Healey, A. P. Hallstrom, K.-H. Kuck, G. Nair, E. P. Schron, R. S. Roberts, C. A. Morillo, and S. J. Connolly
Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias
Eur. Heart J., July 2, 2007; 28(14): 1746 - 1749.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J. Patel and J. T. Heywood
Mode of Death in Patients With Systolic Heart Failure
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 127 - 136.
[Abstract] [PDF]


Home page
Eur Heart JHome page
M. A. Hlatky and D. B. Mark
The high cost of implantable defibrillators
Eur. Heart J., February 2, 2007; 28(4): 388 - 391.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
I. Ferreira-Gonzalez, L. Dos-Subira, and G. H. Guyatt
Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review
Eur. Heart J., February 2, 2007; 28(4): 469 - 477.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
A. Al-Sayegh, A. M. Shukkur, and M. Akbar
Automatic Implantable Cardioverter Defibrillator for the Treatment of Ventricular Fibrillation Following Coronary Artery Spasm: A Case Report
Angiology, February 1, 2007; 58(1): 122 - 125.
[Abstract] [PDF]


Home page
Eur Heart JHome page
S. H. Hohnloser, H. R. Al-Khalidi, C. M. Pratt, J. M. Brum, D. S. Tatla, P. Tchou, P. Dorian, and on behalf of the SHock Inhibition Evaluation with
Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial
Eur. Heart J., December 2, 2006; 27(24): 3027 - 3032.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
T. W. Baron, T. S. Faber, A. Grom, T. Schwab, M. Brunner, A. Geibel, H. Just, C. Bode, and M. Zehender
Real-time assessment of acute myocardial ischaemia by an intra-thoracic 6-lead ECG: evaluation of a new diagnostic option in the implantable defibrillator
Europace, November 1, 2006; 8(11): 994 - 1001.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
P. M. Seferovic, A. D. Ristic, R. Maksimovic, D. S. Simeunovic, G. G. Ristic, G. Radovanovic, D. Seferovic, B. Maisch, and M. Matucci-Cerinic
Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases
Rheumatology, October 1, 2006; 45(suppl_4): iv39 - iv42.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol., September 5, 2006; 48(5): 1064 - 1108.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346.
[Full Text] [PDF]


Home page
Eur Heart JHome page
D. P. Zipes, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
Eur. Heart J., September 1, 2006; 27(17): 2099 - 2140.
[Full Text] [PDF]


Home page
EuropaceHome page
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 746 - 837.
[Full Text] [PDF]


Home page
EuropaceHome page
G. Klein, C. Lissel, A.-C. Fuchs, A. Gardiwal, H. Oswald, M. deSousa, A. M. Pichlmaier, R. Lichtinghagen, H. Geerlings, P. Lippolt, et al.
Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.
Europace, August 1, 2006; 8(8): 618 - 624.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. H. Hohnloser, P. Dorian, R. Roberts, M. Gent, C. W. Israel, E. Fain, J. Champagne, and S. J. Connolly
Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold: The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Trial
Circulation, July 11, 2006; 114(2): 104 - 109.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. S. Chan, K. Stein, T. Chow, M. Fendrick, J. T. Bigger, and S. Vijan
Cost-Effectiveness of a Microvolt T-Wave Alternans Screening Strategy for Implantable Cardioverter-Defibrillator Placement in the MADIT-II-Eligible Population
J. Am. Coll. Cardiol., July 4, 2006; 48(1): 112 - 121.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
K.-H. Kuck and S. Nisam
ICD therapy: 'the sickest benefit the most...': what about the less sick?
Europace, July 1, 2006; 8(7): 508 - 511.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
Z. Goldberger and R. Lampert
Implantable Cardioverter-Defibrillators: Expanding Indications and Technologies
JAMA, February 15, 2006; 295(7): 809 - 818.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. J. Connolly
Use and Misuse of Surrogate Outcomes in Arrhythmia Trials
Circulation, February 14, 2006; 113(6): 764 - 766.
[Full Text] [PDF]


Home page
Eur Heart JHome page
J. P. Pell, M. Corstorphine, A. McConnachie, N. L. Walker, J. C. Caldwell, A. K. Marsden, N. R. Grubb, and S. M. Cobbe
Post-discharge survival following pre-hospital cardiopulmonary arrest due to cardiac aetiology: temporal trends and impact of changes in clinical management
Eur. Heart J., February 2, 2006; 27(4): 406 - 412.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Herlitz
Post-discharge survival following pre-hospital cardiopulmonary arrest owing to cardiac aetiology
Eur. Heart J., February 2, 2006; 27(4): 377 - 378.
[Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
M C S Hall and D M Todd
Modern management of arrhythmias
Postgrad. Med. J., February 1, 2006; 82(964): 117 - 125.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. J. Connolly, P. Dorian, R. S. Roberts, M. Gent, S. Bailin, E. S. Fain, K. Thorpe, J. Champagne, M. Talajic, B. Coutu, et al.
Comparison of {beta}-Blockers, Amiodarone Plus {beta}-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators: The OPTIC Study: A Randomized Trial
JAMA, January 11, 2006; 295(2): 165 - 171.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. D. Krahn, M. Gollob, R. Yee, L. J. Gula, A. C. Skanes, B. D. Walker, and G. J. Klein
Diagnosis of Unexplained Cardiac Arrest: Role of Adrenaline and Procainamide Infusion
Circulation, October 11, 2005; 112(15): 2228 - 2234.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Kadish and M. Mehra
Heart Failure Devices: Implantable Cardioverter-Defibrillators and Biventricular Pacing Therapy
Circulation, June 21, 2005; 111(24): 3327 - 3335.
[Full Text] [PDF]


Home page
Clin TrialsHome page
M. C Simmonds, J. P T Higginsa, L. A Stewartb, J. F Tierneyb, M. J Clarke, and S. G Thompson
Meta-analysis of individual patient data from randomized trials: a review of methods used in practice
Clinical Trials, June 1, 2005; 2(3): 209 - 217.
[Abstract] [PDF]


Home page
CirculationHome page
A. E. Buxton, A. J. Moss, A. E. Buxton, and A. J. Moss
Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator?
Circulation, May 17, 2005; 111(19): 2537 - 2549.
[Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
A Y Patwala and D J Wright
Device based treatment of heart failure
Postgrad. Med. J., May 1, 2005; 81(955): 286 - 291.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. S. Desai, J. C. Fang, W. H. Maisel, and K. L. Baughman
Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-analysis of Randomized Controlled Trials
JAMA, December 15, 2004; 292(23): 2874 - 2879.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Dorian, M. Borggrefe, H. R. Al-Khalidi, S. H. Hohnloser, J. M. Brum, D. S. Tatla, J. Brachmann, R. J. Myerburg, D. S. Cannom, M. van der Laan, et al.
Placebo-Controlled, Randomized Clinical Trial of Azimilide for Prevention of Ventricular Tachyarrhythmias in Patients With an Implantable Cardioverter Defibrillator
Circulation, December 14, 2004; 110(24): 3646 - 3654.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. H. Hohnloser, K. H. Kuck, P. Dorian, R. S. Roberts, J. R. Hampton, R. Hatala, E. Fain, M. Gent, S. J. Connolly, and the DINAMIT Investigators
Prophylactic Use of an Implantable Cardioverter-Defibrillator after Acute Myocardial Infarction
N. Engl. J. Med., December 9, 2004; 351(24): 2481 - 2488.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
D. R. Davis and A. S.L. Tang
Implantable cardioverter defibrillators: therapy against Canada's leading killer
Can. Med. Assoc. J., October 26, 2004; 171(9): 1037 - 1038.
[Full Text] [PDF]


Home page
CMAJHome page
P. Dorian, P. Bogaty, C. E. Buller, B. J. O'Neill, and P. W. Armstrong
Applying the new STEMI guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction
Can. Med. Assoc. J., October 26, 2004; 171(9): 1042 - 1044.
[Full Text] [PDF]


Home page
CMAJHome page
R. Parkash, A. Tang, G. Wells, J. Blackburn, I. Stiell, C. Simpson, P. Dorian, R. Yee, D. Cameron, S. Connolly, et al.
Use of implantable cardioverter defibrillators after out-of-hospital cardiac arrest: a prospective follow-up study
Can. Med. Assoc. J., October 26, 2004; 171(9): 1053 - 1056.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
G. Nichol, P. Kaul, E. Huszti, and J. F.P. Bridges
Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Symptomatic Heart Failure
Ann Intern Med, September 7, 2004; 141(5): 343 - 351.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. J. Wellens
Randomized Clinical Trials: How Long Should They Last?
Circulation, July 13, 2004; 110(2): 107 - 108.
[Full Text] [PDF]


Home page
CirculationHome page
F. Bokhari, D. Newman, M. Greene, V. Korley, I. Mangat, and P. Dorian
Long-Term Comparison of the Implantable Cardioverter Defibrillator Versus Amiodarone: Eleven-Year Follow-Up of a Subset of Patients in the Canadian Implantable Defibrillator Study (CIDS)
Circulation, July 13, 2004; 110(2): 112 - 116.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. D. Swerdlow
Reappraisal of implant testing of implantable cardioverter defibrillators
J. Am. Coll. Cardiol., July 7, 2004; 44(1): 92 - 94.
[Full Text] [PDF]


Home page
Eur Heart JHome page
R. Cappato, S. Boczor, K.-H. Kuck, and on behalf of the CASH Investigators
Response to programmed ventricular stimulation and clinical outcome in cardiac arrest survivors receiving randomised assignment to implantable cardioverter defibrillator or antiarrhythmic drug therapy
Eur. Heart J., April 2, 2004; 25(8): 642 - 649.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
R Gradaus, C Wollmann, J Kobe, D Hammel, S Kotthoff, M Block, G Breithardt, and D Bocker
Potential benefit from implantable cardioverter-defibrillator therapy in children and young adolescents
Heart, March 1, 2004; 90(3): 328 - 329.
[Full Text] [PDF]


Home page
EuropaceHome page
A. Quesada, J.ús Almendral, F. Arribas, R. Ricci, C. Wolpert, P. Adragao, E. Cobo, X. Navarro, and on behalf DATAS investigators
The DATAS rationale and design: a controlled, randomized trial to assess the clinical benefit of dual chamber (DDED) defibrillator
Europace, January 1, 2004; 6(2): 142 - 150.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
E.W. Lau, M.J. Griffith, R.K. Pathmanathan, G.A. Ng, M.M. Clune, J. Cooper, H.J. Marshall, P.R. Forsey, P.J. Stafford, R.G. Gray, et al.
The midlands trial of empirical amiodarone versus electrophysiology-guided interventions and implantable cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death
Europace, January 1, 2004; 6(4): 257 - 266.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. P. DiMarco
Implantable Cardioverter-Defibrillators
N. Engl. J. Med., November 6, 2003; 349(19): 1836 - 1847.
[Full Text] [PDF]


Home page
CirculationHome page
G. Nichol, T. Valenzuela, D. Roe, L. Clark, E. Huszti, and G.A. Wells
Cost Effectiveness of Defibrillation by Targeted Responders in Public Settings
Circulation, August 12, 2003; 108(6): 697 - 703.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
T. Houghton and G. C Kaye
Implantable devices for treating tachyarrhythmias
BMJ, August 9, 2003; 327(7410): 333 - 336.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. V. Jayachandran and D. P. Zipes
Say no to primary prophylaxis with implantable cardioverter-defibrillators in asymptomatic nonischemic dilated cardiomyopathy?
J. Am. Coll. Cardiol., May 21, 2003; 41(10): 1713 - 1715.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. S. Lee, L. D. Green, P. P. Liu, P. Dorian, D. M. Newman, F. C. Grant, J. V. Tu, and D. A. Alter
Effectiveness of implantable defibrillators for preventing arrhythmic events and death: A Meta-Analysis
J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1573 - 1582.
[Abstract] [Full Text] [PDF]


Home page
Emerg. Med. J.Home page
P K Moulik, M N Attar, E L Rose, and A A Khaleeli
Successful resuscitation of a patient with electrical storm
Emerg. Med. J., May 1, 2003; 20(3): e4 - 4.
[Abstract] [Full Text]